Exploring New Standards in Patient Care
Friday, October 30, 2015
The purpose of this symposium is to evaluate the effects of current treatment and discuss new therapies for chronic lymphocytic leukemia (CLL).
At the conclusion of the course, participants should be able to:
- Evaluate the biologic underpinnings that allow the new kinase inhibitors, Ibrutinib and Idelalisib, to have such profound effects on CLL cells and on patient quality of life.
- Develop strategies to incorporate new non-chemotherapeutic therapies into practice as they become available and determine how these might augment and/or replace existing medications.
- Analyze key unanswered questions about the growth, survival, and elimination of CLL clones in patients.
Nicholas Chiorazzi, MD
Investigator, The Feinstein Institute for Medical Research; Head, Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research
Kanti R. Rai, MD
Investigator, Peter Karches Center for Chronic Lymphocytic Leukemia, The Feinstein Institute for Medical Research; Director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center
The Feinstein Institute for Medical Research
The Goldman International Conference Center
350 Community Drive
Manhasset, NY 11030